Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2026)

Bicycle Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $559.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 29.44% year-over-year to $559.5 million; the trailing twelve-month figure through Mar 2026 stood at $559.5 million (down 29.44% YoY), and the FY2025 full-year result was $628.1 million, down 5.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $559.5 million, down from $628.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $961.4 million in Q2 2024, with the low at $100.0 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $543.0 million across 5 years, with a median of $559.5 million in 2026.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 48.95% — and 2023, when it surged 193.81%.
• Bicycle Therapeutics' Cash & Equivalents stood at $339.2 million in 2022, then soared by 55.22% to $526.4 million in 2023, then grew by 26.31% to $664.9 million in 2024, then decreased by 5.53% to $628.1 million in 2025, then dropped by 10.92% to $559.5 million in 2026.
• The last three Cash & Equivalents figures came in at $559.5 million (Q1 2026), $628.1 million (Q4 2025), and $648.3 million (Q3 2025), per Business Quant data.